Literature DB >> 31353328

Idiopathic Short Stature Phenotypes among Korean Children: Cluster Analysis.

Hyo-Kyoung Nam1, Hye Ryun Kim2, Kee-Hyoung Lee2, Young-Jun Rhie3.   

Abstract

Idiopathic short stature (ISS) is a heterogeneous group and their responsiveness to growth hormone treatment varies among individuals. The aim of this study was to identify homogeneous phenotypes to better assess response before the initiation of treatment. We focused on person-centered approaches using a latent profile analysis. Clinical data of 218 children (127 boys and 91 girls) aged 4-15 years were obtained from the "LG Growth Study" which is a non-interventional Korean multicenter registry for growth hormone treatment. Growth hormone dose, first-year difference in height standard deviation score (Δheight SDS), mid-parental height SDS, and initial bone age were inputted into the model. The distribution of scatter plot was clearly distinguished at the chronological age of 8.83 years, Δheight SDS of 0.82 and mean GH dose of 0.36 mg/kg/week. The latent profile analysis revealed three distinct phenotypes names as follows: younger good responder (n = 56), older good responder (n = 111), and older poor responder (n = 51) groups. Despite more than twice the mean growth hormone dose, the older poor responder group showed the least improvement in the mean Δheight SDS. The pretreatment height velocity and peak growth hormone level were lower for the older poor responder group compared with those of the older good responder group. The statistically optimal cutoff point for predicting poor response was 3.41 cm/year for pretreatment height velocity and 9.18 ng/mL for peak growth hormone level. This study offers a new multidimensional approach to enable personalized growth hormone treatment optimization according to ISS phenotypes.

Entities:  

Keywords:  children; cluster analysis; growth hormone; idiopathic short stature; phenotype

Mesh:

Year:  2019        PMID: 31353328     DOI: 10.1620/tjem.248.193

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  4 in total

1.  Effects of high-dose recombinant human growth hormone treatment on IGF-1 and IGFBP-3 levels in idiopathic dwarfism patients.

Authors:  Bin Wu; Honghua Lin; Jian Gao; Juan Sun; Meng Zhao
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 2.340

2.  Association Between Serum Calcium and Phosphorus Levels and Insulin-Like Growth Factor-1 in Chinese Children and Adolescents with Short Stature.

Authors:  Minghui Sun; Wenhua Yan; Qianqian Zhao; Baolan Ji; Bo Ban; Mei Zhang
Journal:  Int J Gen Med       Date:  2020-11-17

3.  Height outcomes in Korean children with idiopathic short stature receiving growth hormone treatment.

Authors:  Hyun Wook Chae; Il-Tae Hwang; Ji-Eun Lee; Cheol Hwan So; Young-Jun Rhie; Jung Sub Lim; Eun Byul Kwon; Kyung Hee Yi; Eun Young Kim; Chae-Ku Jo; Kye Shik Shim; Ha-Yeong Gil; Min-Jeong Seong; Chung Mo Nam; Ji-Su Moon; Jin Soon Hwang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-07       Impact factor: 6.055

4.  Investigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy: LG growth study database.

Authors:  Minsun Kim; Eun Young Kim; Eun Young Kim; Cheol Hwan So; Chan Jong Kim
Journal:  PLoS One       Date:  2021-11-01       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.